Active	Status	Sponsor type	Region	Phase	Filter
11 Active 1 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Liu, Zhigang
TQB2450-III-05, NCT04325763: A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)	Recruiting	3	315	RoW	TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank)	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Stage III Non-small-cell Lung Cancer	12/22	03/25
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Recruiting	3	864	Europe, Canada, Japan, US, RoW	Dostarlimab, Placebo	GlaxoSmithKline	Neoplasms, Head and Neck	05/28	07/29
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Active, not recruiting	3	600	Europe, Canada, US, RoW	Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere	OncoC4, Inc., BioNTech SE	Non Small Cell Lung Cancer	06/26	06/27
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors	Recruiting	1/2	68	RoW	T3011 high dose, T3011 middle dose, T3011 low dose	Shanghai Pharmaceuticals Holding Co., Ltd	Advanced Solid Tumors	12/25	05/26
NCT05842798: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults	Completed	1	28	RoW	TNM002, Placebo	Trinomab Biotech Co., Ltd.	Healthy Volunteers	02/22	02/22